Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer.
Pulmonary arterial hypertension (PAH) is characterized by widespread loss of pulmonary microvasculature. Therefore we hypothesized that angiogenic gene therapy would reverse established PAH, in part restoring the lung microcirculation. Three weeks after monocrotaline (MCT) treatment, Fisher 344 rats were randomized to receive a total of either 1.5 x 10(6) syngeneic fibroblasts (FB) transfected with vascular endothelial growth factor A (VEGF), endothelial NO synthase (eNOS), or null-plasmid transfected FBs. Right ventricular systolic pressure (RVSP) was similarly increased in all MCT-treated groups at the time of gene transfer. Animals receiving the null-vector progressed to severe PAH by Day 35 (P < 0.001). In contrast, eNOS gene transfer significantly reduced RVSP at Day 35 compared with Day 21, whereas VEGF prevented further increases in RVSP over the subsequent 2 wk but did not reverse established PAH. RV hypertrophy was significantly reduced in both the eNOS-treated and VEGF-treated groups compared with the null-transfected controls. Fluorescent microangiography revealed widespread occlusion of the pre-capillary arterioles 21 d after MCT treatment, and animals receiving eNOS gene transfer exhibited the greatest improvement in the arteriolar architecture and capillary perfusion at Day 35. Cell-based eNOS gene transfer was more effective than VEGF in reversing established PAH, associated with evidence of regeneration of pulmonary microcirculation.
Zhao
Yidan D
YD
Division of Cardiology, The Terrence Donnelly Vascular Biology Laboratories, St. Michael's Hospital, Toronto, Ontario, Canada.
Courtman
David W
DW
Ng
Doug S
DS
Robb
Malcolm J
MJ
Deng
Yupu P
YP
Trogadis
Judy
J
Han
Robin N N
RN
Stewart
Duncan J
DJ
D000818:Animals; D005451:Fluorescein Angiography; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics / Q000627:therapeutic use*; D006976:Hypertension, Pulmonary / Q000139:chemically induced / Q000517:prevention & control / Q000628:therapy*; D008168:Lung / Q000098:blood supply / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D016686:Monocrotaline; D052250:Nitric Oxide Synthase Type III / Q000235:genetics* / Q000502:physiology; D011897:Random Allocation; D051381:Rats; D011916:Rats, Inbred F344; D012038:Regeneration; D013997:Time Factors; D042442:Vascular Endothelial Growth Factors / Q000235:genetics
D042442:Vascular Endothelial Growth Factors; D016686:Monocrotaline; D052250:Nitric Oxide Synthase Type III